Article
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.
Drug design, development and therapy - 1 Jan 2014
Swaika Abhisek, Crozier Jennifer A, Joseph Richard W
Abstract excerpt
The discovery of BRAF mutations in the majority of patients with metastatic melanoma combined with the identification of highly selective BRAF inhibitors have revolutionized the treatment of patients with metastatic melanoma. The first highly specific BRAF inhibitor, vemurafenib, began clinical testing in 2008 and moved towards a rapid approval in 2011. Vemurafenib induced responses in ~50% of patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.